Literature DB >> 19573734

The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease.

Jacqueline M Lamour1, Kirk R Kanter, David C Naftel, Maryanne R Chrisant, William R Morrow, Barry S Clemson, James K Kirklin.   

Abstract

OBJECTIVES: We sought to evaluate the outcomes and identify risk factors for mortality after heart transplantation (HT) for congenital heart disease (CHD) in infants, children, and adults.
BACKGROUND: CHD is considered a risk factor for mortality after HT, yet this unique group of patients represents a spectrum of complexity.
METHODS: There were 488 patients transplanted for CHD from the combined Pediatric Heart Transplant Study (1993 to 2002, n = 367) and the Cardiac Transplant Registry Database (1990 to 2002, n = 121) who were analyzed.
RESULTS: The median age at HT was 12.4 years. Primary diagnosis included single ventricle (36%), d-transposition of the great arteries (12%), right ventricular outflow tract lesions (10%), l-transposition of the great arteries (8%), ventricular/atrial septal defects (8%), left ventricular outflow obstruction (8%), and other (18%). Ninety-three percent of patients had at least 1 operation before HT. Survival at 3 months post-HT was significantly worse in CHD patients versus children with cardiomyopathy, but not adults with cardiomyopathy (86%, 94%, and 91%, respectively). There was no difference in conditional 3-month survival among the 3 groups. Five-year survival was 80%. Risk factors for early mortality were older recipient age, older donors with longer ischemic times, and pre-HT Fontan operations. Predicted survival in Fontan patients was lower (77% and 70% at 1 and 5 years) versus non-Fontan patients (88% and 81% at 1 and 5 years). Risk factors for constant phase mortality included younger recipient age, higher transpulmonary gradient, cytomegalovirus mismatch at HT, and earlier classical Glenn operation.
CONCLUSIONS: Patients undergoing transplantation for CHD have a good late survival if they survive the early post-operative period. Risk factors for reduced survival are older age at transplant and a previous Fontan operation.

Entities:  

Mesh:

Year:  2009        PMID: 19573734     DOI: 10.1016/j.jacc.2009.04.020

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  51 in total

1.  Heart Failure in Adults who had the Fontan Procedure: Natural History, Evaluation, and Management.

Authors:  Ari Cedars; Susan Joseph; Philip Ludbrook
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-10

Review 2.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

3.  Heart failure in adult congenital heart disease.

Authors:  Ada Stefanescu; Doreen DeFaria Yeh; David M Dudzinski
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09

Review 4.  Heart Transplantation and Mechanical Circulatory Support in Adults with Congenital Heart Disease.

Authors:  John D Serfas; Priyesh A Patel; Richard A Krasuski
Journal:  Curr Cardiol Rep       Date:  2018-08-09       Impact factor: 2.931

5.  Clinical research priorities in adult congenital heart disease.

Authors:  Timothy Cotts; Paul Khairy; Alexander R Opotowsky; Anitha S John; Anne Marie Valente; Ali N Zaidi; Stephen C Cook; Jamil Aboulhosn; Jennifer Grando Ting; Michelle Gurvitz; Michael J Landzberg; Amy Verstappen; Joseph Kay; Michael Earing; Wayne Franklin; Brian Kogon; Craig S Broberg
Journal:  Int J Cardiol       Date:  2013-12-24       Impact factor: 4.164

Review 6.  Transplantation of the failing Fontan.

Authors:  Amanda D McCormick; Kurt R Schumacher
Journal:  Transl Pediatr       Date:  2019-10

Review 7.  Heart transplantation for adults with congenital heart disease: current status and future prospects.

Authors:  Hikaru Matsuda; Hajime Ichikawa; Takayoshi Ueno; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-04-24

8.  Liver cirrhosis in Fontan patients does not affect 1-year post-heart transplant mortality or markers of liver function.

Authors:  Kathleen E Simpson; Amir Esmaeeli; Geetika Khanna; Francis White; Yumirle Turnmelle; Pirooz Eghtesady; Umar Boston; Charles E Canter
Journal:  J Heart Lung Transplant       Date:  2013-10-25       Impact factor: 10.247

9.  Improved survival after heart transplant for failed Fontan patients with preserved ventricular function.

Authors:  Jacob R Miller; Kathleen E Simpson; Deirdre J Epstein; Timothy S Lancaster; Matthew C Henn; Richard B Schuessler; David T Balzer; Shabana Shahanavaz; Joshua J Murphy; Charles E Canter; Pirooz Eghtesady; Umar S Boston
Journal:  J Heart Lung Transplant       Date:  2016-03-10       Impact factor: 10.247

10.  Fetal aortic valvuloplasty for evolving hypoplastic left heart syndrome: postnatal outcomes of the first 100 patients.

Authors:  Lindsay R Freud; Doff B McElhinney; Audrey C Marshall; Gerald R Marx; Kevin G Friedman; Pedro J del Nido; Sitaram M Emani; Terra Lafranchi; Virginia Silva; Louise E Wilkins-Haug; Carol B Benson; James E Lock; Wayne Tworetzky
Journal:  Circulation       Date:  2014-07-22       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.